Scimeca Dario
Known title: General Counsel and SecretaryCIK: 0001779581
Associated companies
Transaction History
| DTIL | ▼ Sell | Open Market | 4,925 | $19K | 2/18/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 16,667 | $0 | 2/17/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 8,854 | $36K | 1/21/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 14,908 | $0 | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 1,978 | $0 | 1/20/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 8,425 | $0 | 1/20/2026 | View on chart |
| DTIL | ▼ Sell | Open Market | 665 | $4K | 11/3/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 1,835 | $0 | 11/2/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 272 | $1K | 3/4/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 919 | — | 3/3/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 8,928 | $43K | 1/22/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 25,312 | — | 1/20/2025 | View on chart |
| DTIL | ▼ Sell | Open Market | 588 | $5K | 11/4/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 1,836 | $0 | 11/2/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 93 | $1K | 6/10/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 301 | $0 | 6/7/2024 | View on chart |
| DTIL | ▲ Buy | Grant | 833 | $10K | 5/8/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 272 | $3K | 5/2/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 918 | — | 5/1/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 21,287 | $8K | 1/22/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 59,345 | — | 1/20/2024 | View on chart |
| DTIL | ▼ Sell | Open Market | 16,023 | $6K | 11/3/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 55,077 | — | 11/2/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 5,443 | $2K | 8/31/2023 | View on chart |
| DTIL | ▼ Sell | Open Market | 13,361 | $10K | 6/8/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 22,727 | — | 6/7/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,044 | — | 6/7/2023 | View on chart |
| DTIL | ▼ Sell | Open Market | 12,172 | $13K | 3/6/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 27,558 | — | 3/3/2023 | View on chart |
| DTIL | ▲ Buy | Grant | 2,163 | $2K | 2/28/2023 | View on chart |
| DTIL | ▼ Sell | Open Market | 9,833 | $20K | 6/8/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 22,727 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,047 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 2,049 | $7K | 2/28/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 548 | $6K | 8/31/2021 | View on chart |
| DTIL | ▲ Buy | Grant | 2,748 | $13K | 2/26/2021 | View on chart |
| DTIL | ▲ Buy | Grant | 3,156 | $15K | 8/31/2020 | View on chart |
| DTIL | ▲ Buy | Grant | 2,072 | $12K | 2/28/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.